Navigation Links
Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting
Date:12/8/2008

y, Philadelphia, PA; SCHWARZ BIOSCIENCES, Inc., (a member of the UCB Group), Research Triangle Park, NC, United States

Evaluation of Lacosamide Efficacy in Subjects with Partial-Onset Seizures Across the Dose Range Used in Phase II/III Clinical Trials

In the individual trials and pooled analysis in this evaluation, Vimpat(R) significantly reduced seizures at all doses studied (200, 400, and 600 mg/day). The individual trials demonstrated that:

-- The 400 and 600 mg/day Vimpat(R) dose groups were significantly different from placebo for both primary efficacy endpoints in all trials using these doses.

-- The 200 mg/day Vimpat(R) dose group demonstrated significant seizure reduction versus placebo in the phase III trial (SP 755), but not in the phase II trial (SP667). To further evaluate the effectiveness of the 200 mg/day dose, a meta-analysis was conducted; results showed a significant difference compared to placebo for both primary endpoints.

The pooled results among patients entering the maintenance period demonstrated statistically significant reductions in seizure frequency at all doses studied compared to placebo:

-- Seizure frequency was significantly reduced by 33.5 percent for the 200 mg/day group (p <.05 ) and by more than 40 percent for the 400 and 600 mg/day groups (41.4 percent and 48.8 percent, respectively), compared with 19.2 percent for placebo (p<.0001).

-- Responder rates (patients with 50 percent or greater reduction in seizure frequency) were 34.8 percent for 200 mg/day (p <.05), 44.3 percent for 400 mg/day, and 48.6 percent for 600 mg/day, and 23.1 percent for placebo (p<.0001).

-- Additionally, there was a dose-responsive trend for improved seizure freedom rates among subjects who completed the maintenance period (2.7 percent, 3.3 percent, and 4.8 percent with increasing Vimpat(R) doses vs. 0.
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium
2. Derma Sciences Announces Multiple Clinical Posters Featuring MEDIHONEY(R) and ALGICELL Ag(R) to be Presented at Upcoming Wound Care Conference
3. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
4. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
5. Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
6. Environmental Tectonics Corporation Announces a Multiple Sale of Hyperbaric Monoplace Chambers to Comprehensive Healthcare Solutions
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting
10. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
11. Environmental Tectonics Corporation Announces a Multiple Sale for Monoplace Hyperbaric Chambers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Lexington,Kentucky and Queens, New York (PRWEB) October 02, ... is pleased to announce funding received to ... pathway in Alzheimer’s disease. A grant award from ... Institute on Aging (NIA), National Institutes of Health ... as Novel AD Therapeutics." The company also received ...
(Date:10/2/2014)... The National Institutes of Health (NIH) ... today to develop an electrode array system that ... brain works through unprecedented resolution and scale. , ... to support President Obama's BRAIN (Brain Research through ... to revolutionize our understanding of the human mind ...
(Date:10/2/2014)... BRIDGEWATER, N.J. , Oct. 2, 2014 /PRNewswire/ ... in synthetic biology, and Amneal Pharmaceuticals LLC ... volume in the U.S., today announced the formation ... a target active pharmaceutical ingredient (API).  Utilizing Intrexon,s ... collaboration is to develop a consistent, scalable, and ...
(Date:10/1/2014)...  Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the ... of high pressure-based sample preparation systems to the life ... to present at the 2 nd  Global Life ... The Conference will take place at the Warsaw Stock ... Schumacher , President and CEO of PBI, will present ...
Breaking Biology Technology:Gismo Therapeutics Inc. Awarded Grants to Develop New Alzheimer's Disease Therapeutics 2Gismo Therapeutics Inc. Awarded Grants to Develop New Alzheimer's Disease Therapeutics 3NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 2NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 3NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 4Intrexon and Amneal Expand Relationship with Second Product Collaboration 2Intrexon and Amneal Expand Relationship with Second Product Collaboration 3Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland 2Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland 3Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland 4
... HAYWARD, Calif., Jan. 12 Anthera Pharmaceuticals, Inc., ... that it has completed enrollment in its 500 ... Cardiovascular,Inflammation Suppression) clinical trial designed to examine the ... 96 hours of an Acute,Coronary Syndrome (ACS) event. ...
... Md., Jan. 9 Human Genome Sciences, Inc. (Nasdaq: ... at the 27th Annual JPMorgan Healthcare Conference will be ... http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO )A member of Human Genome ... the company on Wednesday, January 14, 2009 at 7:30 ...
... NS, Jan. 9 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), ... present at the OneMedPlace Finance Forum on Tuesday, January ... visit www.onemedplace.com . , Dr. Randal Chase, president ... 8:45 am PST on the development of its superior ...
Cached Biology Technology:Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial 2Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial 3
(Date:9/30/2014)... it comes to using marijuana, new research, involving mice ... Journal of Leukocyte Biology , suggests ... that you should. That,s because a team of Italian ... do serious long-term damage to the immune system. This ... diseases, such as multiple sclerosis, inflammatory bowel disease and ...
(Date:9/30/2014)... Mass. , Sept. 30, 2014 /PRNewswire/ ... control solutions for the biotech and power ... its new RECONN Bioprocess Manager, an easy-to-use ... solution geared towards bioprocess development laboratories. ... have disparate bioreactor and analyzer systems. Accessing ...
(Date:9/29/2014)... exposure to tar tended to be lower for smokers ... exposure to nicotine tended to be lower. , Slim ... several countries around the world. Previous studies have shown ... smoke of these cigarettes are lower than those in ... the smoke are not necessarily linked to a reduced ...
Breaking Biology News(10 mins):Adolescent exposure to thc may cause immune systems to go up in smoke 2Spectra Automation Introduces RECONN Bioprocess Manager 2Slim cigarette smokers not exposed to more harmful chemicals 2
... the Arctic is boosted by global warming, it,s not enough ... permafrost beneath the surface, University of Florida researchers have found ... thawing of permafrost in a warming world. Twice as ... the atmosphere today, and what happens to it as it ...
... the first time in mammalian brain cells, researchers at ... in building the circuitry that relays signals through the ... aging process in the brain, the researchers say. Additionally, ... discovery paves the way for faster progress toward identifying ...
... back on a shark" is the take home message from ... Erich Ritter of the Shark Research Institute and Raid Amin ... that sharks can comprehend body orientation and therefore know whether ... to approach and possibly attack their prey from the blind ...
Cached Biology News:UF researchers' experiment is first to simulate warming of Arctic permafrost 2UF researchers' experiment is first to simulate warming of Arctic permafrost 3Gene found to be crucial for formation of certain brain circuitry 2Sharks prefer to sneak up from behind, study shows 2
Required to perform reference file generation, flatfield calibration and performance verification processes on the GSD-501...
ssDNA from PCR DNA in less than 1 hour. No gels, columns, or slurries. Sequence from high quality ssDNA: clearer reads, longer runs....
... of Freezerworks Unlimited includes 2 clients and streamlines ... the sharing of freezers by multiple groups without ... Network Client/Server version for ... monitor with 256 colors; OS 8.6 & OS ...
Applications: Immunohistochemistry, ISH, FISH, CISH....
Biology Products: